Pre-metastatic niches in distant tissue facilitate metastasis from the primary tumor. Cargo-free 15 porous polymer scaffolds implanted in tumor-bearing mice act as synthetic metastatic niches 16 recruiting metastasizing cancer cells. Herein, we investigated the mechanisms by which these 17 implants attract cancer cells from circulation. Scaffolds attract cancer cells in part via 18 S100A8/A9 secreted by Gr1 + myeloid cells in a mechanism that mimics lung metastasis. Further, 19 cancer cells attracted to the scaffold have a lung-tropic gene expression signature regardless of 20 their tissue of origin. The scaffold implant reduces metastasis to the lung suggesting otherwise 21 lung-tropic cancer cells are diverted to the scaffold. The suppression of metastatic spread by the 22 scaffold suggests this mechanism may be exploited for novel therapies, and may broadly 23 influence the design of scaffold-based drug delivery system for anti-cancer therapy. 24 25 30 metastasizing cancer cells before they are detectable in native organs 5, 6 , show potential as a 31 therapeutic by reducing metastatic tumor burden in native organs 6 , and can be engineered and 32 humanized to uniquely study human pathways in native pre-metastatic niche progression 6-9 .
Introduction 26
The development of the pre-metastatic niche in native tissues facilitates metastasis by attracting 27 cancer cells from circulation and providing a supportive microenvironment 1-3 . Cargo-free porous 28 polymer scaffolds implanted in hosts bearing breast cancers develop a local microenvironment 29 that functions as a synthetic pre-metastatic niche 4-9 . Synthetic pre-metastatic niches can capture implants. We initially investigated the role of scaffold size and number on cancer cell 48 recruitment ( Fig. 1A and Supplementary Figs 1 and 2) . Cargo-free porous polymer scaffolds 49 recruit metastasizing cancer cells from the primary tumor in orthotopic 4T1 murine breast cancer 50 models that develop spontaneous metastasis 5, 6 . Interestingly, a large scaffold implant recruited 51 substantially more metastasizing cancer cells than a small scaffold ( Fig. 1A and Supplementary 52 Fig. 1 ), yet the ratio of cancer cells to all cells at the implant remained the same regardless of 53 scaffold size ( Supplementary Fig. 2 ). We also found that the number of cancer cells captured per 54 scaffold did not vary with the number of implants per mouse ( Fig. 1A ), suggesting that the local 55 microenvironment of each scaffold in tumor-bearing mice was responsible for cancer cell 56 recruitment. 57 The role of diseased conditioning of the scaffold on cancer cell recruitment was next analyzed by 58 performing intracardiac injections 14 of tdTomato-labeled 4T1 cancer cells (4T1/tdTomato/Luc 59 cells) in scaffold-bearing BALB/c mice that either had an unlabeled 4T1 cell primary tumor 60 (diseased) or no tumor (healthy). After 24 hours, we observed that 5-fold more tdTomato-61 positive 4T1 cells had migrated from the blood into the scaffolds and lungs of the tumor-bearing 62 mice than the tumor-free mice ( Fig. 1B and Supplementary Fig. 3 ). These in vivo results suggest 63 that cells in the diseased scaffolds and lungs may secrete factors that actively induce the 64 extravasation of 4T1 cells from the blood. This hypothesis was tested with media conditioned by Using flow cytometry, we observed a 5 to 6-fold increase in myeloid cells (CD11b + Gr1 + ) in the 73 scaffolds and lungs of diseased mice compared to healthy mice ( Fig. 2A, B and Supplementary 74 Fig. 4 ). These myeloid cells were predominately granulocytic (CD11b + Gr1 + Ly6G + ) rather than 75 monocytic (CD11b + Gr1 + Ly6C + ). Macrophages (CD11b + F4/80 + ) and dendritic cells 76 (CD11c + F4/80 -) were reduced in the diseased scaffolds and lungs while no statistically 77 significant changes were observed in other cell types at the scaffold. We next prepared 78 conditioned media from multiple diseased scaffold cell populations using Magnetically Assisted
79
Cell Sorting (MACS) on various surface markers. We found that cell subpopulations that 80 included granulocytic myeloid cells (CD45 + leukocytes, Gr1 + myeloid cells, and Ly6G + 81 granulocytic myeloid cells) greatly enhanced transmigration of 4T1 cells in our in vitro 82 extravasation model ( Fig. 2C and Supplementary Fig. 5 ). 83 We also found that S100A8/A9 mRNA expression and secreted protein in the diseased scaffold 84 and lung were greatly upregulated relative to healthy tissue ( Fig. 3A, B ). Previous work has 85 shown that myeloid cell secreted S100A8/A9 is a potent chemoattractant for metastasizing 86 cancer cells at the pre-metastatic lung 15, 16 . At the diseased scaffold, S100A8/A9 mRNA and 87 secreted protein was primarily from cell subpopulations containing granulocytic myeloid cells 88 (CD45 + leukocytes, Gr1 + myeloid cells, and Ly6G + granulocytic myeloid cells) ( Fig. 3C, D) . Just 89 as in the scaffold, Gr1 + myeloid cells in the lung were responsible for most S100A8/A9 mRNA 90 expression and protein secretion ( Fig. 3E , F). Neutralizing S100A8/A9 bioactivity in Gr1 + 91 myeloid cell conditioned media with an anti-S100A8/A9 antibody eliminated the increase in 4T1 92 cell transmigration for both lung and diseased scaffold conditions ( Fig. 3G and Supplementary 93 Fig. 6 ). We also demonstrated that the activity of the anti-S100A8/A9 antibody was specific to 94 S100A8/A9 by observing that it reduced 4T1 cell transmigration towards soluble recombinant 95 S100A8/A9 protein ( Fig. 3G and Supplementary Fig. 6 ), but not towards 0.1% fetal bovine 96 serum (FBS) (control, Supplementary Fig. 7 ). 97 S100A8/A9 induces a lung-tropic gene signature in breast cancer cells attracted to the 98 scaffold implant. We next compared the gene expression of transmigrated 4T1 cells (TEM+ 99 cells) in vitro to those that did not transmigrate (TEM-cells) ( CCL2 and 0.1% FBS, induced neither signature in transmigrated 4T1 cells ( Fig. 4A ). Autocrine 109 signaling through S100A8/A9 is known to amplify myeloid cell recruitment and increase 110 S100A8/A9 at the pre-metastatic lung 15, 16, 20 . Interestingly, we found that initiating 4T1 cancer 111 cells may participate in similar autocrine signaling to recruit following 4T1 cells. 4T1 cell 112 populations that were first to transmigrate towards disease scaffolds, diseased lung, or 113 S100A8/A9 protein overexpressed Rage, S100a8, and S100a9 (Fig. 4A ). Subsequent 114 transmigrating cancer cells had lower expression of these genes, which diluted the overall 115 difference between transmigrated and non-transmigrated 4T1 cells ( Supplementary Fig. 8 ).
116
Our attempts to isolate and expand 4T1 cells directly from diseased lung and scaffold tissue for 117 validation of these results in vivo were unsuccessful due to technical limitations. However, we 118 were able to isolate cancer cells from diseased lung and scaffold using MDA-MB-231BR human 119 breast cancer cells 21 . Both the diseased lung and scaffold isolated cancer cell lines aligned with 120 the lung-tropic gene expression signature, but not the bone-tropic signature, demonstrating the 121 lung-like recruitment mechanism towards the cargo-free scaffold implants in vivo (Fig. 4A ). We 122 also observed Rage and S100a9 overexpression in these cell lines relative to the parent line, 123 suggesting that the cancer cell S100A8/A9 autocrine loop might be present at the synthetic pre-124 metastatic niche in vivo ( Fig. 4A ).
125
Collectively, these results show that the key chemoattractant in the pre-metastatic niche, whether 126 native or synthetic, can selectively recruit the metastatic cancer cell subpopulation with the 127 specific phenotype associated with organotropic metastasis. This finding suggests that synthetic Supplementary Fig. 9 ). As was the case for the 4T1 breast cancer cell line, the differential gene 137 expression signature of transmigrated cells aligned with a lung-tropic rather than bone-tropic 138 signature ( Fig. 4C ). These results suggest that the diseased scaffold induces a common and 139 universal lung-tropic cellular phenotype in recruited cancer cells similar to that found for cancer 140 cells recruited to the lung 17 .
141
In aggregate, these results show that cargo-free porous polymer scaffolds act as synthetic 142 metastatic niches that mimic the lung's S100A8/A9 recruitment axis. As in the lung, myeloid 143 cells at the scaffold implant secrete soluble S100A8/A9 to recruit metastasizing cancer cells, Supplementary Figs 11-15 ). 155 We first examined whether 4T1 cells that trafficked to the scaffold implant remained viable or 156 died sometime after reaching the implant. We used our intracardiac injection model to introduce 157 4T1/tdTomato/Luc cells into circulation in mice bearing unlabeled 4T1 primary tumors ( Fig. 5B,   158 schematic). In this model, the bolus of tdTomato and Luc labeled 4T1 cancer cells introduced 159 into circulation by intracardiac injection is clear within 1 to 2 days 23 . We therefore quantified the 160 abundance of 4T1/tdTomato/Luc cells in the scaffolds and lungs 1 day and 12 days after 161 intracardiac injection. While we observed far more 4T1/tdTomato/Luc cells in the lungs 12 days 162 after intracardiac injection than 1 day ( Fig. 5B and Supplementary Figs 11 and 12 ), indicating 163 massive proliferation, there were far fewer 4T1/tdTomato/Luc cells at the scaffold on day 12 164 than on day 1 ( Fig. 5B and Supplementary Figs 11 and 13 ), indicating lack of proliferation and 165 cell death. These results strikingly demonstrate a tumoricidal property of the synthetic metastatic 166 niche implant toward metastatic cancer cells that may contribute to its utility as a potential 167 therapeutic.
168
In BALB/c mice that were initially orthotopically inoculated with fluorescent 4T1/tdTomato/Luc 169 cancer cells (Fig. 5C, schematic) , cancer cells metastasized to the scaffold implant from primary 170 tumor by 7 days after inoculation ( Fig. 5C and Supplementary Figs 14 and 15 ). Accumulation of 171 cancer cells at the scaffold reached a peak at day 21, possibly due to abundant circulating tumor 172 cells in the blood at this time point. By day 28, the number of cancer cells per scaffold 173 ( Supplementary Fig. 15a ) as well as the ratio of cancer cells to total cells at the scaffold ( Fig. 5C   174 and Supplementary Fig. 14) had decreased despite the total cells recovered per scaffold 175 remaining constant across time ( Supplementary Fig. 15b ). In contrast, the cancer cells that 176 colonized the lung massively expanded from days 21 to 28, developing into macrometastases by 177 day 28 (Fig. 5C ), necessitating endpoint for the experiment. These results further support the 178 conclusion that the microenvironment of the scaffolds does not support tumor cell outgrowth.
179
In aggregate, these results suggest that lung-tropic metastatic cancer cells that would otherwise 180 metastasize to the lung are attracted to the synthetic pre-metastatic niche via S100A8/A9 and are 181 prevented from forming secondary tumors in the scaffold implants. Further supporting this 182 mechanism, we observed that scaffold implants suppressed the development of lung metastasis 183 without influencing the growth of primary tumor in the orthotopic 4T1 breast cancer model ( Fig.   184 5D and Supplementary Figs 16 and 17) . Additional studies that investigate the mechanisms 185 underlying the differential outgrowth within the lung and scaffold may inspire novel therapeutics 186 for metastasis.
187
Our findings are broadly useful across the emerging field of scaffold-based local delivery system 188 for anti-cancer therapy 10, 11 , including in the design of vaccine 24 , drug 25 Competing financial interests 215 The authors declare no competing financial interests. 
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Conditioned media prepared with cells from diseased scaffolds and lung stimulated more transendothelial migration of 4T1 cancer 300 cells than conditioned media produced with cells from healthy mice. Scale bar = 150 µm. **p < 0.01, from student t-test. All 301 experiments were performed three times with similar results. 
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Gene expression and protein secretion of S100A8/A9 are up-regulated in diseased scaffolds and lungs relative to healthy tissue.
316
(C, D) Gene expression and protein secretion of S100A8/A9 is predominately in cell subpopulations that contain granulocytic 317 myeloid cells (CD45 + leukocytes, Gr1 + myeloid cells, and Ly6G + granulocytic myeloid cells). (E, F) S100A8/A9 is 
